5-氮杂-2&rsquo;-脱氧胞苷通过反转原钙黏蛋白10表达抑制人乳腺癌细胞系MDA-MB-231的侵袭和迁移

张微 朱文斌 岳丽玲 刘立琨*

doi:10.16098/j.issn.0529-1356.2019.04.010

PDF(4805 KB)

解剖学报 ›› 2019, Vol. 50 ›› Issue (4) : 465-470. DOI: 10.16098/j.issn.0529-1356.2019.04.010

肿瘤生物学

5-氮杂-2’-脱氧胞苷通过反转原钙黏蛋白10表达抑制人乳腺癌细胞系MDA-MB-231的侵袭和迁移

张微^1,2 朱文斌¹ 岳丽玲¹ 刘立琨^1*

作者信息 +

Effect of protocadherins 10 re-expression induced by 5-aza-2’-deoxycytidine on invasion and migration capacity of breast cancer cell line MDA-MB-231 and its mechanism

ZHANG Wei ^1,2 ZHU Wen-bin¹ YUE Li-ling¹ LIU Li-kun^1*

Author information +

文章历史 +

摘要

目的探讨5-氮杂-2’-脱氧胞苷（5-Aza-CdR）诱导抑癌基因原钙黏蛋白10（PCDH10）重新表达对人乳腺癌细胞MDA-MB-231体外侵袭迁移能力的影响并初步探讨其机制。方法体外培养人乳腺癌细胞MDA-MB-231，设置对照组和5-Aza-CdR药物处理组，分别采用反转录聚合酶链反应（RT-PCR）检测PCDH10 mRNA 的表达水平；Transwell法和划痕实验检测细胞的侵袭迁移能力；Western blotting检测PCDH10、DNA甲基转移酶（DNMT）3A、DNMT3B、核因子（NF）-κB p65和基质金属蛋白酶（MMP）-2、MMP-9蛋白表达的变化。结果 5-Aza-CdR能够反转PCDH10的mRNA和蛋白表达；PCDH10表达恢复后MDA-MB-231细胞的侵袭迁移能力受到抑制；Western blotting检测发现，MDA-MB-231细胞经5-Aza-CdR处理后DNMT3A、DNMT3B、NF-κB p65、MMP-2和MMP-9的表达下调。结论 5-Aza-CdR可抑制MDA-MB-231细胞DNMT3A和DNMT3B的表达，使抑癌基因PCDH10表达恢复，从而通过阻滞NF-κB p65的活化，下调MMP-2和MMP-9表达而抑制乳腺癌细胞的侵袭转移。

Abstract

Objective To investigate whether re-expression of protocadherin 10(PCDH10) induced by 5-aza-2’-deoxycytidine (5-Aza-CdR) could affect the invasion and migration of MDA-MB-231 cells, and to explore the possible mechanism. Methods Human breast cancer cell line MDA-MB-231 was cultured in vitro. Control group and 5-Aza-CdR treatment group were set up. PCDH10 mRNA expression in MDA-MB-231 cell line was determined by reverse transcription-polymerase chain reaction (RT-PCR); Transwell chamber and wound healing assay were performed to measure the invasion and migration capacity of the cells, and protein expression of PCDH10, DNA methyltransferase(DNMT)3A, DNMT3B, nuclear factor(NF)-κB p65, matrix metalloproteinases(MMP)-2 and MMP-9 were detec Western blotting. Results 5-Aza-CdR could reverse the methylation status of PCDH10 gene in MDA-MB-231 cells in a dose-dependent manner. Re-expression of PCDH10 significantly inhibited cell invasion and migration capacity in vitro. Western blottoing analysis revealed that the expression of DNMT3A, DNMT3B, NF-κB p65, MMP-2 and MMP-9 in MDA-MB-231 cells were down-regulated after exposure to 5-Aza-CdR. Conclusion Re-expression of PCDH10 significantly inhibits MDA-MB-231 invasion and migration capacity. The inhibitory effect is characterized that 5-Aza-CdR treatment down-regulates DNMT3A and DNMT3B levels, recovers the expression of anti-oncogene PCDH10, further blocks the activation of NF-κB p65, resultsing in a decrease in the secretion of MMP-2 and MMP-9.

导出引用

张微朱文斌岳丽玲刘立琨. 5-氮杂-2’-脱氧胞苷通过反转原钙黏蛋白10表达抑制人乳腺癌细胞系MDA-MB-231的侵袭和迁移[J]. 解剖学报. 2019, 50(4): 465-470 https://doi.org/10.16098/j.issn.0529-1356.2019.04.010

ZHANG Wei ZHU Wen-bin YUE Li-ling LIU Li-kun. Effect of protocadherins 10 re-expression induced by 5-aza-2’-deoxycytidine on invasion and migration capacity of breast cancer cell line MDA-MB-231 and its mechanism[J]. Acta Anatomica Sinica. 2019, 50(4): 465-470 https://doi.org/10.16098/j.issn.0529-1356.2019.04.010

参考文献

［1］ Desantis C, Siegel R, Bandi P, et al. Breast cancer statistics, 2011［J］. Ca Cancer J Clin, 2011, 61(6):409-418.

［2］ Hossain MS, Ferdous S, Karim-Kos HE. Breast cancer in South Asia: a Bangladeshi perspective［J］. Cancer Epidemiol, 2014, 38(5):465-470.

［3］ Zoon CK, Starker EQ, Wilson AM, et al. Current molecular diagnostics of breast cancer and the potential incorporation of microRNA［J］. Expert Rev Mol Diagn, 2009, 9(5):455-467.

［4］ Voduc KD, Cheang MCU, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse［J］. J Clin Oncol, 2011, 22(3):302-304.

［5］ O’Driscoll L, Clynes M. Biomarkers and multiple drug resistance in breast cancer［J］. Curr Cancer Drug Tar, 2006, 6(5):365-384.

［6］ Pathiraja TN, Stearns V, Oesterreich S. Epigenetic regulation in estrogen receptor positive breast cancer-role in treatment response［J］. J Mammary Gland Biol, 2010, 15(1):35-47.

［7］ Yang X, Jia M, Li Z, et al. Bioinformatics analysis of aggressive behavior of breast cancer via an integrated gene regulatory network［J］. J Cancer Res Ther, 2014, 10(4):1013-1018.

［8］ Bertrand KC, Mack SC, Northcott PA, et al. PCDH10, is a candidate tumour suppressor gene in medulloblastoma［J］. Child Nerv Syst, 2011, 27(8):1243-1249.

［9］ Zhong X, Zhu Y, Mao J, et al. Frequent epigenetic silencing of PCDH10, by methylation in human colorectal cancer［J］. J Cancer Res Clin, 2013, 139(3):485-490.

［10］ Lin YL, Li ZG, He ZK, et al. Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer［J］. J Int Med Res, 2012, 40(6):2117-2123.

［11］ Hu X, Sui X, Li L, et al. Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers［J］. J Pathol, 2013, 229(1):62-73.

［12］ Shi D, Murty VV, Gu W. PCDH10, a novel p53 transcriptional target in regulating cell migration［J］. Cell Cycle, 2015, 14(6):857-866.

［13］ Liu LK, Zhu WB, Liu DSh, et al. Methylation of endothelin receptor B gene in four breast cancer cell lines and its effect on MCF-7 cell proliferation［J］. Acta Anatomica Sinica, 2018, 49(5):611-616. (in Chinese)

刘立琨, 朱文斌, 刘得水, 等. 4株乳腺癌细胞中内皮素受体B基因的甲基化状态及对MCF-7细胞增殖的影响［J］. 解剖学报, 2018, 49(5):611-616.

［14］ Ying J, Li HT, Langford C, et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation［J］. Oncogene, 2006, 25(7):1070-1080.

［15］ Harada H, Miyamoto K, Yamashita Y, et al. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage Ⅰ non-small-cell lung cancer［J］. Cancer Med, 2015, 4(10):1536-1546.

［16］ Zhong X, Shen H, Mao JS, et al. Epigenetic silencing of protocadherin 10 in colorectal cancer［J］. Oncol Lett, 2017, 13(4):2449-2453.

［17］ Bhat S, Kabekkodu SP, Varghese VK, et al. Aberrant gene-specific DNA methylation signature analysis in cervical cancer［J］. Tumour Biol, 2017, 39(3):1-16.

［18］ Ye MX, Li JZ, Gong JP. PCDH10 gene inhibits cell proliferation and induces cell apoptosis by inhibiting the PI3K/Akt signaling pathway in hepatocellular carcinoma cells［J］. Oncol Rep, 2017, 37(6):3167-3174.

［19］ Pimson C, Ekalaksananan T, Pientong C, et al. Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer［J］. Peer J, 2016, 4(7):e2112.

［20］ Shao Y, Zhang W, Zhang C, et al. High-resolution melting analysis of BLU methylation levels in gastric, colorectal, and pancreatic cancers［J］. Med Oncol, 2010, 27(3):998-1004.

［21］ Schneider-Stock R, Diab-Assef M, Rohrbeck A, et al. 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45-and p53-dependent mechanisms［J］. J Pharmacol Exp Ther, 2005, 312(2):525-536.

［22］ Wang H, Zhu Y, Zhao M, et al. miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin beta and matrix metalloproteinase 2(MMP2)［J］. PLoS One, 2013, 8(8):e70192.

［23］ Bai XY, Li SJ, Wang M, et al. Kruppel-like factor 9 down-regulates matrix metalloproteinase 9 transcription and suppresses human brease cancer invasion［J］. Cancer Lett, 2018, 412(2):224-235.

［24］ Ennen M, Klotz R, Touche N, et al. DDB2: a novel regulator of NF-κB and breast tumor invasion［J］. Cancer Res, 2013, 73(16):5040-5052.

［25］ Xu P, Cai F, Liu X, et al. Sesamin inhibits lipopolysaccharide-induced proliferation and invasion through the p38-MAPK and NF-κB signaling pathways in prostate cancer cells［J］. Oncol Rep, 2015, 33(6):3117-3123.

［26］ Li Z, Yang Z, Peng X, et al. Nuclear factor-κB is involved in the protocadherin-10-mediated pro-apoptotic effect in multiple myeloma［J］. Mol Med Rep, 2014, 10(2):832-838.